• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Anesthetic Effect - Pipeline Review, H2 2012 Product Image

Anesthetic Effect - Pipeline Review, H2 2012

  • Published: October 2012
  • 74 pages
  • Global Markets Direct

Anesthetic Effect – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Anesthetic Effect - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Anesthetic Effect, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anesthetic Effect. Anesthetic Effect - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Anesthetic Effect.
- A review of the Anesthetic Effect products under development by companies and universities/research institutes READ MORE >

2
List of Tables 6
List of Figures 7
Introduction 8
REPORT COVERAGE 8
Anesthetic Effect Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Anesthetic Effect 10
Anesthetic Effect Therapeutics under Development by Companies 12
Anesthetic Effect Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Anesthetic Effect Therapeutics – Products under Development by Companies 20
Anesthetic Effect Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Anesthetic Effect Therapeutics Development 22
Merck & Co., Inc. 22
PAION AG 23
Paladin Labs Inc. 24
Futura Medical plc. 25
Xel Pharmaceuticals, Inc. 26
Physica Pharma 27
ISDIN 28
Encore Therapeutics Inc. 29
Sihuan Pharmaceutical Holdings Group Ltd. 30
Anesthetic Effect – Therapeutics Assessment 31
Assessment by Monotherapy Products 31
Assessment by Combination Products 32
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
RAD-100 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
sugammadex sodium - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
XEL-006LG - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
propofol - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CNS-7056 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
methoxycarbonyl etomidate - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
dexmedetomidine hydrochloride - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Org-25435 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
lidocaine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Thiopental + Propofol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
dexmedetomidine hydrochloride - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ketamine hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
magnesium sulfate - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Remifentanil + Propofol + Dexmedetomidine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
lidocaine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
midazolam hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
isoflurane - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
lidocaine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PF0713 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
ropivacaine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
nalmefene - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Lidocaine + Epinephrine + Sufentanil - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
ropivacaine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ropivacaine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Anesthetic Effect Therapeutics – Drug Profile Updates 63
Anesthetic Effect Therapeutics – Discontinued Products 64
Anesthetic Effect Therapeutics - Dormant Products 65
Anesthetic Effect – Product Development Milestones 66
Featured News & Press Releases 66
Jul 25, 2012: Nuvo Research Announces New Listing Of Synera Patent In FDA Orange Book 66
May 14, 2012: Ono Pharma Announces Phase II Study Results Of ONO-2745/CNS 7056 66
Oct 14, 2011: APP Pharmaceuticals Announces Increased Availability Of APP Diprivan And APP Propofol 1% 67
Sep 26, 2011: Encore Therapeutics Announces Extended Release Depot Formulation Of Ropivacaine Available For License 67
May 31, 2011: PAION Receives Second Milestone Payment Of $3m From Ono Pharmaceutical Through Start Of Japanese Phase II With Remimazolam 68
Nov 22, 2010: PAION Reports Positive Results Of CNS 7056 In Phase IIb Study In Colonoscopy 68
Sep 27, 2010: PAION Completes Phase IIb Study With CNS 7056 69
Aug 02, 2010: PAION Announces Recruitment Of Phase IIb Trial With CNS 7056 70
Apr 27, 2010: Paion Reaches Agreement With FDA On Phase IIb Study Design For CNS 7056 In Patients Undergoing Colonoscopy 71
Feb 01, 2010: Allergan Announces FDA Approval Of JUVEDERM XC Dermal Filler Formulated With Lidocaine 72
Appendix 73
Methodology 73
Coverage 73
Secondary Research 73
Primary Research 73
Expert Panel Validation 73
Contact Us 74
Disclaimer 74

List of Tables
Number of Products Under Development for Anesthetic Effect, H2 2012 10
Products under Development for Anesthetic Effect – Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Investigation by Universities/Institutes, H2 2012 15
Comparative Analysis by Late Stage Development, H2 2012 16
Comparative Analysis by Mid Clinical Stage Development, H2 2012 17
Comparative Analysis by Early Clinical Stage Development, H2 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 19
Products under Development by Companies, H2 2012 20
Products under Investigation by Universities/Institutes, H2 2012 21
Merck & Co., Inc., H2 2012 22
PAION AG, H2 2012 23
Paladin Labs Inc., H2 2012 24
Futura Medical plc., H2 2012 25
Xel Pharmaceuticals, Inc., H2 2012 26
Physica Pharma, H2 2012 27
ISDIN, H2 2012 28
Encore Therapeutics Inc., H2 2012 29
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 30
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Stage and Molecule Type, H2 2012 36
Anesthetic Effect Therapeutics – Drug Profile Updates 63
Anesthetic Effect Therapeutics – Discontinued Products 64
Anesthetic Effect Therapeutics – Dormant Products 65

List of Figures
Number of Products under Development for Anesthetic Effect, H2 2012 10
Products under Development for Anesthetic Effect – Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 14
Late Stage Products, H2 2012 16
Mid Clinical Stage Products, H2 2012 17
Early Clinical Stage Products, H2 2012 18
Discovery and Pre-Clinical Stage Products, H2 2012 19
Assessment by Monotherapy Products, H2 2012 31
Assessment by Combination Products, H2 2012 32
Assessment by Route of Administration, H2 2012 33
Assessment by Stage and Route of Administration, H2 2012 34
Assessment by Molecule Type, H2 2012 35
Assessment by Stage and Molecule Type, H2 2012 36

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos